Trial Profile
Safety and Tolerability of Multiple Ascending Doses of LY2608204 in Patients With Type 2 Diabetes Mellitus.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Nov 2018
Price :
$35
*
At a glance
- Drugs LY 2608204 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Eli Lilly and Company (India) Pvt. Ltd
- 01 Apr 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 02 Feb 2011 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.
- 06 Dec 2010 New trial record